公开(公告)号：US20230381237A1

公开(公告)日：2023-11-30

申请号：US18325930

申请日：2023-05-30

申请人： CytoAgents, Inc.

发明人： Jodi CRAIGO ,  Teresa WHALEN ,  Heather Lynn NOTTINGHAM ,  Arthur P. BERTOLINO

IPC分类号： A61K35/17 ,  A61K31/5585 ,  A61P35/00 ,  A61K9/00

CPC分类号： A61K35/17 ,  A61K31/5585 ,  A61P35/00 ,  A61K9/0019

摘要： Methods, compositions, and kits that can be used to treat cytokine release syndrome, ICANS, or both, associated with CAR T-cell administration are described herein. For example, pharmaceutical compositions containing beraprost, beraprost isomers, or salts thereof can be used as an adjuvant therapy with chimeric antigen receptor T cells (CAR T-cells) to treat cancer while reducing or eliminating undesired and potentially dangerous side effects.

公开(公告)号：US20230255892A1

公开(公告)日：2023-08-17

申请号：US17991697

申请日：2022-11-21

申请人： Supernus Pharmaceuticals, Inc.

发明人： Argaw Kidane ,  Padmanabh P Bhatt

IPC分类号： A61K9/28 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/5585 ,  A61K31/192

CPC分类号： A61K9/282 ,  A61K9/0004 ,  A61K9/28 ,  A61K9/286 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/2013 ,  A61K9/2077 ,  A61K9/2826 ,  A61K31/192 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/5585

摘要： An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.

公开(公告)号：US11666615B2

公开(公告)日：2023-06-06

申请号：US16783717

申请日：2020-02-06

申请人： Tadashi Tanabe ,  Keiichi Hukuda ,  Takashi Kawakami

发明人： Tadashi Tanabe ,  Keiichi Hukuda ,  Takashi Kawakami

IPC分类号： A61K35/76 ,  A61K31/5585 ,  A61K38/18 ,  A61K38/52 ,  A61K45/06 ,  A61K48/00 ,  C12N7/00 ,  A61K35/13

CPC分类号： A61K35/76 ,  A61K31/5585 ,  A61K38/1825 ,  A61K38/1833 ,  A61K38/1866 ,  A61K38/52 ,  A61K45/06 ,  A61K48/005 ,  C12N7/00 ,  C12Y503/99004 ,  A61K35/13 ,  C12N2750/14132 ,  C12N2750/14143 ,  C12N2799/025 ,  A61K38/1866 ,  A61K2300/00 ,  A61K38/1825 ,  A61K2300/00 ,  A61K38/1833 ,  A61K2300/00 ,  A61K38/52 ,  A61K2300/00

摘要： The present invention relates to a method for inducing production of vascular endothelial growth factor (VEGF). The method includes administering, to an individual, a composition including adeno-associated virus (AAV) carrying a hPGIS gene coding for human prostacyclin synthase (hPGIS) which synthesizes prostaglandin I2 (PGI2).

公开(公告)号：US11666602B2

公开(公告)日：2023-06-06

申请号：US16124532

申请日：2018-09-07

申请人： United Therapeutics Corporation

发明人： Roger Jeffs ,  Thomas Petersen ,  Roger M. Ilagan ,  Michael Wade

IPC分类号： A61K31/192 ,  A61K35/28 ,  A61K35/44 ,  A61K45/06 ,  C12N5/0775 ,  A61K31/5585 ,  C12N5/071 ,  A61K48/00 ,  A61K35/12

CPC分类号： A61K35/28 ,  A61K31/192 ,  A61K31/5585 ,  A61K35/44 ,  A61K45/06 ,  C12N5/0663 ,  C12N5/0692 ,  A61K48/005 ,  A61K2035/124 ,  C12N2501/02 ,  A61K31/5585 ,  A61K2300/00 ,  A61K35/28 ,  A61K2300/00

摘要： The application is directed to a method for treating or preventing vasculopathy comprising administrating to a subject in need thereof a pharmaceutical composition comprising mesenchymal precursor cells (MPCs) and a prostacyclin. Also provided a method for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.

公开(公告)号：US20180246123A9

公开(公告)日：2018-08-30

申请号：US15562259

申请日：2016-03-22

申请人： Sisse Rye OSTROWSKI ,  Pär Ingemar JOHANSSON

发明人： Sisse Rye OSTROWSKI ,  Pär Ingemar JOHANSSON

IPC分类号： G01N33/68 ,  G01N33/58 ,  A61K31/5585 ,  A61K45/06

CPC分类号： G01N33/6893 ,  A61K31/5585 ,  A61K45/06 ,  A61K2300/00 ,  G01N33/58 ,  G01N33/68

摘要： Use of prostacyclin or an analogue thereof for treatment of a new medical indication in acute critically ill patients, in particular acute critically ill patients with systemic endothelial damage, a biomarker for identifying individuals that have a new medical indication, and a method for identifying a new medical indication.

公开(公告)号：US20160367640A1

公开(公告)日：2016-12-22

申请号：US15259101

申请日：2016-09-08

申请人： Eli Lilly and Company

发明人： Michael Edward Christe ,  Thomas Andrew Hardy

IPC分类号： A61K38/28 ,  A61K47/10 ,  A61K47/02 ,  A61K31/192

CPC分类号： A61K38/28 ,  A61K31/192 ,  A61K31/5575 ,  A61K31/5585 ,  A61K47/02 ,  A61K47/10 ,  A61K2300/00

摘要： The invention is a composition of human insulin or insulin analog that includes treprostinil and that has faster pharmacokinetic action than commercial formulations of existing insulin analog products.

摘要翻译： 本发明是人胰岛素或胰岛素类似物的组合物，其包括曲前列素，并且比现有胰岛素类似物产品的商业制剂具有更快的药代动力学作用。

公开(公告)号：US09504695B2

公开(公告)日：2016-11-29

申请号：US14509680

申请日：2014-10-08

申请人： Topokine Therapeutics, Inc.

发明人： Murat V. Kalayoglu

IPC分类号： A61K31/5575 ,  C07C405/00 ,  A61P3/04 ,  A61K31/5585 ,  C07C69/732 ,  C07C235/30 ,  C07D307/20 ,  A61K31/133

CPC分类号： A61K31/5575 ,  A61K9/0014 ,  A61K31/133 ,  A61K31/5585 ,  C07C69/732 ,  C07C235/30 ,  C07D307/20

摘要： Provided are methods, compositions, systems, and kits for treating metabolic syndrome or a disorder associated with metabolic syndrome, e.g., obesity, dyslipidemia, and/or a diabetic condition, comprising administering systemically to a subject one or more compounds of the Formula (I) and/or (II): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein , L, R1, R2, Z, X, A and B are defined herein.

公开(公告)号：US20160263042A1

公开(公告)日：2016-09-15

申请号：US15162829

申请日：2016-05-24

申请人： Supernus Pharmaceuticals, Inc.

发明人： Argaw Kidane ,  Padmanabh P Bhatt

IPC分类号： A61K9/28 ,  A61K9/00 ,  A61K31/192

CPC分类号： A61K9/282 ,  A61K9/0004 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/2013 ,  A61K9/2077 ,  A61K9/28 ,  A61K9/2826 ,  A61K9/286 ,  A61K31/192 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/5585

摘要： An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.

公开(公告)号：US09439952B2

公开(公告)日：2016-09-13

申请号：US14781342

申请日：2015-05-04

申请人： Eli Lilly and Company

发明人： Michael Edward Christe ,  Thomas Andrew Hardy

IPC分类号： A61K38/28 ,  A61K31/5585 ,  A61K31/5575

CPC分类号： A61K38/28 ,  A61K31/192 ,  A61K31/5575 ,  A61K31/5585 ,  A61K47/02 ,  A61K47/10 ,  A61K2300/00

摘要： The invention is a composition of human insulin or insulin analog that includes treprostinil and that has faster pharmacokinetic action than commercial formulations of existing insulin analog products.

摘要翻译： 本发明是人胰岛素或胰岛素类似物的组合物，其包括曲前列素，并且比现有胰岛素类似物产品的商业制剂具有更快的药代动力学作用。

公开(公告)号：US09402852B2

公开(公告)日：2016-08-02

申请号：US12445986

申请日：2007-10-22

申请人： Leonard I. Zon ,  Trista E. North ,  Wolfram Goessling

发明人： Leonard I. Zon ,  Trista E. North ,  Wolfram Goessling

IPC分类号： A61K31/557

CPC分类号： A61K31/5575 ,  A61K31/201 ,  A61K31/404 ,  A61K31/41 ,  A61K31/557 ,  A61K31/558 ,  A61K31/5585 ,  A61K31/655 ,  A61K33/14

摘要： The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by a particular indication by modulating the PG or Wnt signaling pathways, or employing modulators of both PG and Wnt signaling pathways for a synergistic effect or highly selective effect.

摘要翻译： 本发明提供使用组织生长调节剂调节组织生长的组合物和方法，其是通过调节PG或Wnt信号传导途径增强或抑制特定指示所需的组织生长或使用PG和W​​nt的调节剂的试剂 用于协同效应或高选择性效应的信号通路。